REVIEW ARTICLE

Avoiding harm: Tackling problematic polypharmacy through strengthening expert generalist practice

Joanne Reeve

Academy of Primary Care, Hull York Medical School, UK

Correspondence
Professor Joanne Reeve, Academy of Primary Care, Hull York Medical School, Allam Medical Building, Cottingham Road, Hull HU6 7RX, UK. Email: joanne.reeve@hyms.ac.uk

Problematic polypharmacy is a growing challenge. Medication that is intended to improve patients’ health and wellbeing is instead becoming part of the problem. The way we practice medicine has become a driver for the problem. Dealing with the challenge will need us to think differently about how we do clinical care.

A 2013 Kings Fund report stated that tackling problematic polypharmacy requires us to actively build a principle of compromise into the way we use medicines. There are implications for how we consult and make decisions with patients, in how we design health practice and systems to support that decision making, and, in our understanding of the process of research, how we generate the knowledge that informs practice.

This review considers the current state of play in all 3 areas and identifies some of the work we still need to do in order to generate the practice-based evidence needed to tackle this most challenging problem.

Finding a way to redesign practice to address problematic polypharmacy could offer a template for tackling other related complex issues facing medical practice such as multimorbidity, chronic pain and complex mental health.

KEYWORDS
generalism, multimorbidity, polypharmacy, problematic polypharmacy

1 | THE CHALLENGE OF PROBLEMATIC POLYPHARMACY

Polypharmacy is now a routine medical intervention. Defined as the concomitant use of multiple medicines on a long-term basis, it represents an approach to medical care that has expanded significantly in scale and scope over the last 20 years. Around 1/3 of people aged 75 and over take 6 medicines or more a day. The last 2 decades have seen the number of people prescribed 5+ medicines a day increase 4-fold.

Appropriate polypharmacy offers significant potential benefit to both individual and population health. However, the 2013 Kings Fund report also recognises a new challenge—that of problematic polypharmacy. A person on 10 or more medicines a day is over 3 times more likely to be admitted to hospital than someone on 1–3 medicines per day. The risk of adverse reactions and medication errors increases with higher prescribing. Forty percent of people taking 5 or more medicines a day report feeling burdened by their use. Many factors contribute to problematic polypharmacy, including patient, professional and health system issues. The Kings Fund therefore defines problematic polypharmacy with reference to what is experienced by the patient: being when the “intended benefit of the medication is not realised.” This definition requires us to consider explicitly what we mean by ‘intended benefit’.

Work to date to address the challenges associated with polypharmacy has centred on the principles of medicines optimisation: ‘ensuring people get the right choice of medicines, at the right time, and are engaged in the process by the clinical team’. In practice, this focuses on the safe and effective use of medicines to enable the best outcomes, involving whole practice teams in safely delivering medicines to patients. The intended benefit is optimal medical impact from medication with minimal side effects or risk.
Medicines optimisation programmes have been criticised for a lack of person-centred focus in defining best practice and outcomes with relation to decisions about medication use. Indeed, the 2013 Kings Fund report described that addressing problematic polypharmacy would require compromise between medical and patient perspectives on the use of medicines. Intended benefit may still be biomedical outcomes. For some patients, priorities for care may reflect different benefits.

Achieving compromise in order to meet whole-person needs is the expertise of the medical generalist. Generalist practice describes the skills needed to integrate biomedical and biographical perspectives of individual illness to generate an individually tailored interpretation of what is wrong and what needs doing. The goal of generalist practice is to support health as a resource for daily living—a means to an end rather than the end itself. Generalist skills offer a mechanism to deliver robust, safe compromise.

However, the 2019 NHS Long Term Plan recognises a shortage of capacity of generalist skills in the hospital setting. In the community/primary care setting, research highlights 4 barriers to use of generalist skills in practice and in particular with reference to decision making around prescribing practice. A 2017 survey of prescribers including general practitioners (GPs), pharmacists and nurse prescribers described that tailoring of medicines was inhibited by the 4Ps of Permission, Prioritisation, Professional training and Performance management. Professionals described a perceived lack of permission to work beyond guidelines—an approach needed to achieve tailoring and compromise. They highlighted a failure to prioritise this complex task in a multitude of other competing priorities in their daily work, meaning that they lacked the ‘head space’ to tailor medication use. People described both a lack of professional training in the complex decision making required for tailoring, exacerbated by a lack of confidence in using the skills they did have. Finally, they challenged performance management processes, which at best ignored, and at worse criticised, this area of practice.

As yet, and for a variety of reasons that I shall return to, we have no evidence-based description of an expert—generalist-prescribing intervention. However, we do have a growing body of research evidence and professional scholarship that offers us insights into how we could overcome the described barriers. This review aims to provide an evidence-informed overview of the state of play and proposes next actions for avoiding harm from problematic polypharmacy through strengthening expert generalist practice.

2 | BUILDING A GENERALIST RESPONSE

This review will therefore consider: how can strengthening expert generalist practice support the compromise needed to tackle problematic polypharmacy? Underpinning generalist medical practice and the delivery of compromise is the principle of person-centred care: that care is guided by the needs and preferences of the individual, recognising health as a resource for living and not an end in itself. Healthcare decisions require an interpretation of illness and need based on understanding of the individual in their context, not just their disease status. Delivering person-centred care is a complex intellectual task, and certainly not a soft skill.

To explore this further, I will examine 3 areas of practice: the consultation (the clinical intervention), the practice setting (the context), and scaling and sustaining practice (implications for research and scholarship).

3 | RETHINKING THE CONSULTATION

Compromise needs an approach to clinical practice that supports robust and safe construction of contextualised meaning driving clinical decision making. Generalist practice constructs whole-person-centred meaning in context through the integration of knowledge/evidence on both the biomedical and biographical aspects of individual illness experience. Decisions are informed by, rather than based on, guidelines/evidence, with a clinician exercising the skills and clinical judgement of the expert generalist to robustly work beyond guidelines to deliver whole-person tailored care. Clinicians (health care professionals from across multiple disciplines) using generalist skills create new, tailored knowledge through everyday practice.

A (still limited) body of scholarship describes how these clinicians work beyond guidelines in practice. Gabbay’s account of generating practice-based evidence, and the construction of mindlines, describes how GPs actively construct knowledge-in-practice-in-context through the use of clinical scholarship. Similarly, Donner-Banzhoff used ethnographic methods to observe GPs in practice, and described the inductive foraging used by the GPs to construct tailored understanding of patients’ illness and needs. Both bodies of research describe the knowledge work undertaken (in these cases) by GPs to robustly construct tailored interpretations in context. Through professional discussion, we have described these actions as the clinical scholarship of professional practice.

The importance of this interpretive practice—the exercise of clinical judgement—is recognised within key systems that currently govern clinical practice. The National Institute for Health and Care Excellence (NICE) produces most UK guidelines describing best practice. The Chair of NICE, Professor Haslam, has repeatedly described that NICE produces “guidelines not tramlines”, with all NICE documents calling for professional judgement. Guidelines are constructed from a review of best evidence (see Box 1). The evidence-based medicine (EBM) movement also supports the use of clinical judgement in deciding if and when to apply evidence to an individual patient. Both NICE and EBM emphasise the importance of clinical judgement. However, neither provides a robust account describing how we can recognise good clinical judgement and in particular, how this judgement can be distinguished from the clinical opinion that appears at the bottom of the EBM hierarchy of evidence.

As highlighted in my own research, and within informal discussions with colleagues, clinicians feel that they lack the skills and confidence to robustly defend clinical judgement and beyond protocol decisions. Professional training (and assessment) focuses on...
The recommendations in this guideline represent the views of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guidance fully in to account, alongside the needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guidance does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them, their families or carer or guardian.

“Demonstrating what you know, rather than how you make use of what you know (for example, to deliver tailored decisions). Professionals feel unable to defend complex decisions, and so they do not make them. This undermines the capacity for compromise, and so contributes to problematic polypharmacy.”

**BOX 1** Statement of use within National Institute for Health and Care Excellence (NICE) guidelines

The School for Advancing Generalist Expertise (SAGE) 5 Steps consultation model describes the epistemological principles (5 steps) needed to support robust generation of knowledge in practice in context—see Box 2. Clinicians should pay attention to, and document their thinking/decision making, with reference to: a clear statement of goals of care with the default being to support health for daily living; a considered exploration of a full data set; the construction of a tailored explanation; a clear process of professional safety netting; and follow up of the patient for impact assessment. This fifth step recognises that a tailored explanation is always an interpretation constructed to support a goal. The quality of the interpretation lies in the process of its construction (the first 4 stages) but also its utility—whether it offers value to an outcome.

The SAGE 5 Steps model provides a framework that addresses each of the 4P barriers to tailored decision making previously described in recognising the legitimacy of professional interpretive practice, and the complexity of the task (and so prioritisation). It provides a framework to support the application of skills, and an epistemologically robust framework for critically reviewing and defending decision making; as well as performance management/assessment.

Both the clinical tools described and the SAGE 5 Steps model can be understood as complex interventions supporting professional practice. As such, they can—and should—be subjected to critical evaluation through research in order to understand the impacts on professional practice and patient outcomes. The principles behind the SAGE model have been assessed within quality improvement activity. Both models describe principles of practice that will be recognised by and familiar to many professionals:

“The good physician treats the disease. The great physician treats the person who has the disease” (Osler) [cited by Centor].

However, formal research evaluation of either consultation approach has yet to be done.

**4 | RESPONDING TO THE CHALLENGE: TOOLS FOR GENERALIST PRESCRIBING?**

A number of tools have been developed to help clinicians “approach the challenge of inappropriate polypharmacy”. In the UK, these include the Seven Steps to appropriate polypharmacy in the Scottish Polypharmacy Guidance; Barnett’s Seven Steps to a patient-centred approach to managing polypharmacy in England; and the All Wales Medicines Strategy Group Polypharmacy: guidance for prescribing. All describe the need to undertake a person-centred assessment of medicines use in an individual, which considers the goals of care, reasons for taking individual medicines, and an understanding of medication adherence or resistance.

Mangin and colleagues reviewed approaches for reducing inappropriate medication use from across the world and generated a set of 10 recommendations for reducing inappropriate medication use. These include encouraging clinicians to always consider opportunities for deprescribing when undertaking medication reviews; correcting the lack of research evidence of outcomes on person, rather than disease, focused, medicines use; and highlighting the need for tailored prescribing decisions.

What is missing to date from the described models of prescribing practice is explicit recognition of a key barrier to tailored prescribing, namely clinicians’ perception of a lack of permission, skills and confidence in *beyond protocol* decision making. This gap was recognised by Mangin et al in their review, which called for a “return to the original concept of EBM”, restoring the role of a thoughtful professional “rather than a disease or algorithm technician”. Addressing this gap requires attention to the process of knowledge generation (robust interpretation) in practice. Drawing on the scientific principles of epistemology (the theory of knowledge including how we judge between different types of knowledge), I have described a framework (consultation model) that can be used to both support and establish the trustworthiness of that aspect of clinical practice.
Successful implementation of new ways of working requires us to pay attention to the context as well as the intervention itself. For generalist expertise to improve the compromise needed to address problematic polypharmacy, we need to look not just at what clinicians and patients are doing, but also to think about the organisation of practice.

Repeat prescribing supporting long-term medication use occurs mainly in the primary care (general practice) context. In the UK in 2018, 1.1 billion prescription items were dispensed in the community, at a cost of £8.8 billion. Improvements to the organisation of prescribing practice has come through the development of Medicines Optimisation systems. The principle behind NHS England Medicines Optimisation programme is simple: to “improve outcomes and value.” Measures to achieve these goals include the introduction of practice systems that improve outcomes for patients by helping them take their medicines correctly, avoid unnecessary medicines and reduce wastage, and improve safety. Medicines Optimisation has contributed to significant improvements in practice areas such as antibiotic prescribing and reducing the use of medicines that are not clinically or cost effective. Utilising the clinical skills of pharmacy teams within primary care settings has been a crucial part of this success.

But Medicines Optimisation approaches, to date, have not fully embraced the challenge of implementing compromise and in particular the 4Ps to generalist practice that my work has described. The principles of Medicines Optimisation recognise the importance of a patient-centred approach (see Box 3) and so potentially addresses permission as a barrier to person-centred care. However, as described practice models do not offer specific guidance on how to ensure that principle #1 (understanding the patient’s experience) should be used to guide or moderate choices raised by principle #2 (evidence based use of medicines). The approaches to strengthen generalist expertise within the SAGE 5 Steps model may help address this challenge.

However, further work is also needed to tackle the wider organisational barriers to achieving compromise in practice. As discussed, these include how to appropriately prioritise the work needed within the wider context of a primary care service, how to build the teams and resources needed to support professional practice, and how to appropriately performance manage this complex area of work. Again, the research literature offers us insights into how we might address these wider organisational gaps and challenges, including the use of burden measurement tools to identify patients most at risk; building continuity of approach across communities of practice; and the revision of performance management tools (see Table 1).

As yet, there are no research studies that pull all of these factors together to evaluate a new generalist complex intervention to address problematic polypharmacy. We do have a Cochrane review evaluating the impact of introducing evidence-based medicines optimisation tools (e.g. STOPP-START, Beers criteria, medication appropriateness index) to address polypharmacy. Results demonstrate improved quality and safety governance outcomes (for example, a
1. Aim to understand the patient’s experience
2. Evidence based choice of medicines
3. Ensure medicines use is as safe as possible
4. Make medicines optimisation part of routine practice

**BOX 3** Medicines optimisation: Four principles of a patient-centred approach

**TABLE 1** Potential practice level changes driving improvement in compromise/expert generalist prescribing

| BARRIER                          | POTENTIAL SOLUTION                                                                 |
|---------------------------------|-------------------------------------------------------------------------------------|
| Prioritisation                  | Identifying patients experiencing problematic polypharmacy                           |
|                                 | 40% of patients taking 5+ medicines a day feel burdened by their medication. This group may benefit from a generalist review and discussion of compromise, but 60% of people do not feel burdened. Polypharmacy is potentially appropriate, and they may not benefit from additional review. Using burden tools such as the living with medicines questionnaire offers a way to identify and prioritise patients who may need a different approach. |
|                                 | Patients have different expectations of medicines, which affects the way they use, and/or resist, medicines. Prioritising goal setting with patients is important. |
|                                 | Frailty is commonly viewed as a marker of vulnerability to burden and problematic polypharmacy—and is a risk factor commonly recorded in primary care practice in the UK. However Reeve and Bancroft’s quality improvement work suggested that factors predicting need for generalist review are not captured solely by biomedical parameters, but relate to issues such as mental health and social support. These observations are supported by empirical research looking at experiences of living with long-term conditions. Prioritisation of patients may need to focus on nonbiomedical parameters |
| Prioritising and protecting professional time | In 2013, practitioners told us that they did not have time to tailor clinical decisions in trying to fit busy consultations in to short time periods. In 2017, a repeat survey now revealed that clinicians did not have the head space. Practitioners are now regularly engaged in a volume and array of decision making. What has been described as the cognitive load upon clinicians is ever growing. Even with more time, longer consultations, clinicians do not have the capacity to manage the volume of knowledge work expected of them: in dealing with complex medical conditions, in contributing to major new configuration of services, in managing growing levels of uncertainty. A solution focused on longer consultation time with patients, that does not recognise the wider calls on professional load is unlikely to be successful. |
| Professional practice: communities of practice | Gabbay recognised the importance of teams to support beyond protocol decision making and the generation of contextually relevant, collective practice-based-evidence (mindlines) from the evidence-based-guidelines-for-practice that come from outside of the practice context. With general practice teams evolving, and GP roles change, implications for supporting compromise and complex decision making need to be thought through. Sharing the data needed for exploration of problems, and the interpretive practice of decision making (see Box 1), requires continuity of approach across a team of clinicians, and across a primary and secondary care interface. |
| Performance management           | Performance management drives clinical actions. For example, a review of the Scottish Quality and Outcomes framework concluded that performance management led to more bureaucratic, less individualised care with an increasing biomedical focus. Revitalising generalist (whole-person-centred) care will need a review and revision of performance management tools. |

Reduction in biomedically defined inappropriate prescribing) but with uncertain evidence of benefit for clinically significant outcomes and patient-centred care. Newer studies now seek to evaluate multi-faceted (complex) interventions that recognise the range of clinician, patient and context components needed to address problematic polypharmacy. Each study has a slightly different focus for its intervention. It is likely that we will need innovative research methods, for example realist synthesis, to help us integrate the findings and so draw wider conclusions on redesigning prescribing practice.

**6 | IMPLICATIONS FOR RESEARCH AND SCHOLARSHIP**

This current body of research will provide us with proof of concept statements: evidence of what could work to address problems associated with polypharmacy. What comes next is the implementation stage—assessing whether the principle works when we seek to deliver it at scale in the primary care setting. Implementing complex interventions into everyday practice and at scale requires yet another set of knowledge and skills.
However, there is a common theme running through each stage discussed here: the theme of knowledge work and the robust generation and application of knowledge in, and for, practice.\textsuperscript{17,18,43,49} At a consultation level, the generalist clinician works to integrate biomedical and biographical understanding of illness to generate new knowledge-in-practice of compromise. At a practice level, the generalist team works to integrate the multiple elements needed to enable and support this complex knowledge work. Now, at the systems level, clinicians and academics must work together to integrate the knowledge and insights from their different contexts to co-produce solutions to shared problems.

Evans and Scarborough recognised this process as a new understanding of how research works.\textsuperscript{43} Their observations of health services research in action revealed 2 types of practice: bridging and blurring. Bridging refers to the (perhaps) more traditional review of scholarship and research: where objective knowledge is generated in a controlled setting, with the use of new knowledge translation tools and workers to deliver this new understanding to the context in which it is to be used. They also observed examples of blurring: where academics and applied workers came together to co-produce new knowledge-in-context. The clinical practice of tailored prescribing involves the generation of knowledge-in-practice-in-context.\textsuperscript{14} Arguably therefore, the generation of robust research evidence describing the mechanisms and impact of such practice requires methodological approaches able to deal with this blurring.

Evans and Scarborough did not seek to judge between the approaches they observed.\textsuperscript{43} However, they did note that both produce different types of knowledge and so raise questions for us on how we judge best evidence. Our understanding of best evidence is currently largely driven by the epistemological assumptions of the EBM movement.\textsuperscript{20} EBM shapes both our understanding of best knowledge for practice (as discussed), and also best methods for producing knowledge (through research). The EBM hierarchy of evidence judges between different types of knowledge based on the methodology used to generate it. However, EBM was originally developed within a specialist, biomedical setting and the epistemological assumptions (and so hierarchy) reflect the ontological beliefs and knowledge work of that context. However, these biomedical assumptions about best evidence have now been applied more broadly across health care setting including into areas which require attention to beyond biomedical thinking. One unintended consequence has been a negative impact on achieving the clinical compromises discussed here.\textsuperscript{15,27}

Glassiou and Chalmers have challenged the current methodology-based definition of best evidence on the grounds that it is contributing to research waste: the generation of research that does not deliver any impact.\textsuperscript{44,45} They propose that research should instead be judged by 3 components: the relevance or appropriateness of the research question, the appropriateness of the methodology for the question, and the impact of the research. Their broader vision of research quality may offer a framework by which to judge the generation of knowledge from a blurred model of research that reverses the current direction of flow of knowledge translation.\textsuperscript{46} Instead of focusing on the implementation of biomedical research in practice (evidence-based practice), we may also use, for example, Living Lab models\textsuperscript{47} to capture the daily scholarship of clinicians\textsuperscript{18} and patients\textsuperscript{5} alike in order to generate the practice-based evidence\textsuperscript{46} needed to develop tailored healthcare.

7 | CONCLUSION

Building compromise into the way we practice medicine, and use medication, will need changes to the way we make, use and evaluate clinical decisions—the knowledge work of clinical practice. The expertise of generalist practice, built on the robust generation of tailored interpretations of illness need; and informed, but not driven by, disease-focused evidence, offers a way forward. In the UK, the need, and urgency, for this shift in direction has been recognised recently in the publication of the Future Doctor Programme,\textsuperscript{48} and by the work of the WISE GP programme (www.wisegp.co.uk).\textsuperscript{49}

Building capacity for clinical compromise will require changes in the way we design and deliver healthcare. This review has highlighted the need for a sustained shift in goals of healthcare, recognising quality defined by whole-person outcomes (capacity to live daily life); in the training, ongoing professional support and performance management of healthcare professionals; and in the design of systems supporting learning from practice, including research. Tackling problematic polypharmacy will need whole system changes to address barriers to the generation, use and assessment of knowledge for practice in real-time and in context.

We have an opportunity to address a key clinical challenge: how to tailor medical care to the needs of the individual patient. Finding a way to redesign practice to address problematic polypharmacy could also offer a template for tackling other related complex issues facing medical practice such as multimorbidity, chronic pain and complex mental health. In tackling problematic polypharmacy, we may also describe a new model for evidence-informed innovation of practice for the holy grail of whole-person-centred healthcare.

COMPETING INTERESTS

There are no competing interests to declare.

ORCID

Joanne Reeve \textsuperscript{a} https://orcid.org/0000-0002-3184-7955

REFERENCES

1. Duerrden M, Avery T, Payne R. Polypharmacy and medicines optimisation. Making it safe and sound https://www.kingsfund.org.uk/sites/default/files/field_publication_file/polypharmacy-and-medicines-optimisation-kingsfund-nov13.pdf (accessed 30 July 2020).
2. EDeN: English Deprescribing Network Briefing. April 2019. https://www.sps.nhs.uk/articles/english-deprescribing-network-resource-paper/ (accessed 30 July 2020).
3. Payne RA, Abel GA, Avery AJ, Mercer SW, Mo R. Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. Br J Clin Pharmacol. 2014;77(6):1073-1082.
4. Kraska J, Katusiime B, Corlett SA. Patient experiences of the burden of using medicines for long-term conditions and factors affecting
burden: a cross-sectional survey, Health Soc Care Community. 2018;26(6):946-959.

5. NHS England. Medicines Optimisation. https://www.england.nhs.uk/medicines-2/medicines-optimisation/ (accessed 6 June 2020)

6. Heaton J, Britten N, Kr ska J, Reeve J. Person-centred medicines optimisation policy in England: an agenda for research on polypharmacy. Prior Health Care Res Dev. 2017;18(1):24-34.

7. Reeve J, Blakeman T, Freeman GK, et al. Generalist solutions to complex problems: generating practice-based evidence - the example of managing multi-morbidity. BMC Fam Pract. 2013;14(1):112. https://doi.org/10.1186/1471-2296-14-112

8. NHS England. The NHS Long Term Plan. Growing the medical workforce 2019. https://www.longtermplan.nhs.uk/online-version/chapter-4-nhs-staff-will-get-the-backing-they-need/3-growing-the-medical-workforce/ (accessed 30 July 2020)

9. Reeve J, Dowrick C, Freeman G, et al. Examining the practice of generalist expertise: a qualitative study identifying constraints and solutions. J the Royal Soc Med Short Rep. 2013;4:204253313510155.

10. Reeve J, Fleming J, Britten N, Byng R, Kr ska J, Heaton J. Identifying enablers and barriers to individually tailored (expert generalist) prescribing: a survey of English health care professionals. BMC Fam Pract. 2018;19(1):17.

11. Person Centred Coordinated Care. Cocreating health care: what is P3C? https://www.p3c.org/ (accessed 30 July 2020)

12. Williamson DL, Carr J. Health as a resource for everyday life: advancing the conceptualization. Crit Public Health. 2009;19(1):107-122.

13. Donner-Banzhoff N, Hertwig R. Inductive foraging: improving the diagnostic yield of primary care consultations. Eur J Gen Pract. 2014;20(1):69-73.

14. Higgs J, Jones MA, Loftus S, Christenson N. Clinical reasoning in the health professions. 3rd ed. London: Elsevier Ltd. 2008.

15. Reeve J. Interpretive medicine: supporting generalism in a changing primary care world. Occs Pap R Coll Gen Pract. 2010;88(i-viii):1-20.

16. Gabbay J, le May A. Practice-based evidence for healthcare. Clinical mindlines. London: Routledge: 2011.

17. Panopto. What is a knowledge worker? https://www.panopto.com/blog/what-is-a-knowledge-worker/ (accessed 30 July 2020)

18. Reeve J, Firth A. Revitalising general practice: unleashing our inner scholar. Br J Gen Pract. 2017;67(659):266.

19. Haslam D. Getting the evidence right. 2016. https://www.nice.org.uk/news/feature/david-haslam-getting-the-guidance-right (accessed 30 July 2020)

20. Sackett DL, Straus SE. Evidence Based Medicine: how to practice and teach EBM. 2nd ed. Churchill Livingstone; 2000.

21. Reeve J. Time to retire evidence based medicine? Generalist care needs scholarship based medicine. B J Gen Pract. 2018;88:390-391.

22. Wenzel RP. Medical education in the era of alternative facts. N Engl J Med. 2017;377(7):607-609.

23. NICE. 2019. Multimorbidity and polypharmacy. www.nice.org.uk/advice/ktt18/chapter-evidence-context (accessed 30 July 2020).

24. NHS Scotland. Polypharmacy Guidance: Medicines Review. 2020 http://www.polypharmacy.scot.nhs.uk/polypharmacy-guidance-medicines-review/ (accessed 30 July 2020).

25. Specialist Pharmacy Service. 2014 A patient centred approach to polypharmacy. www.sps.nhs.uk/articles/polypharmacy-oligopharmacy-deprescribing-resources-to-support-local-delivery/ (accessed 30 July 2020)

26. All Wales Medicines Strategy Group. Polypharmacy: guidance for prescribing. 2014 http://www.awmsg.org/docs/awmsg/medman/Polypharmacy%20-%20Guidance%20for%20Prescribing.pdf (accessed 30 July 2020)

27. Mangin D, Bahat G, Golomb B, et al. International Group for Reducing Inappropriate Medication use & polypharmacy (IGRIMUP): position statement and ten recommendations for action. Drugs Aging. 2018;35(7):575-587.

28. Reeve J. Supporting expert generalist practice: the SAGE consultation model. Br J Gen Pract. 2015;35:207-208.

29. Reeve J, Bancroft R. Generalist solutions to overprescribing: a joint challenge for clinical and academic primary care. Prim Health Care Res Dev. 2014;15(1):72-79.

30. Centor RM. To be a great physician, you must understand the whole story. Medscape Gen Med. 2007;9(1):39.

31. Doherty A, Boland P, Reed J, et al. Barriers and facilitators to deprescribing in primary care: a systematic review. BJGP Open. 2020. https://doi.org/10.3399/bjgpopen20X101096

32. Lau R, Stevenson F, Ong BN, et al. Effectiveness of strategies to facilitate uptake or implementation of complex interventions: a systematic review of systematic reviews. Implement Soc. 2015;10(suppl1):A67.

33. NHS Digital. Prescription cost analysis England 2018. https://files.digital.nhs.uk/E5/A014AS/PCA-eng-2018-report.pdf (accessed 30 July 2020).

34. Cooper JA, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. BMJ Open. 5:e009235.

35. Patton DE, Francis JJ, Clark E, et al. A pilot study of the S-MAP (solutions for medication adherence problems) intervention for older adults prescribed polypharmacy in primary care: a study protocol. Pilot and Feasib Stud. 2019;9(1):116.

36. Muth C, Uhlimann L, Haefeli WE, et al. Effectiveness of a complex intervention on Prioritising medication in multimorbidity (PRIMUM) in primary care: results of a pragmatic cluster randomised controlled trial. BMJ Open. 2018;8(2):e017740.

37. Sinnott C, Byrne M, Bradley CP. Improving medication management for patients with multimorbidity in primary care: a qualitative feasibility study of the MY COMRADE implementation intervention. Pilot and Feasib Stud. 2017;3(1):14.

38. Mangin D, Lamarche L. 2016. Team approach to Polypharmacy Evaluation and Reduction (TAPER-RCT). https://clinicaltrials.gov/ct2/show/NCT02942927?term=polypharmacy%2C+mangin (accessed 30 July 2020)

39. Hughes C, Rankin A. 2019. Appropriate Polypharmacy in Older People in Primary Care (PolyPrime) https://clinicaltrials.gov/ct2/show/NCT01418187 (accessed 30 July 2020)

40. Threapleton CJD, Kimpton JE, Carey IM, et al. Development of a structured clinical pharmacology review for specialist support for management of complex polypharmacy in primary care. Br J Clin Pharmacol. 2020;86(7):1326-1335. https://doi.org/10.1111/bcp.14243

41. Rycroft-Malone J, McCormack B, Hutchinson AM, et al. Realist synthesis: illustrating the method for implementation research. Implement Sci. 2012;7(1):33.

42. May C, Rapley T, Mair FS et al. 2015. Normalization Process Theory On-line users' Manual, Toolkit and NoMAD instrument. http://normalizationprocess.org/ (accessed 30 July 2020)

43. Evans S, Scarborough H. Supporting knowledge translation though collaborative translational research initiatives: 'bridging' versus 'blurring' boundary-spanning initiatives in the UK CLAHRIC initiative. Soc Sci Med. 2014;106:119-127.

44. Glassi ou P, Vandenbroucke J, Chalmers I. Assessing the quality of reporting of research evidence. The Lancet. 2009;374(9683):86-89.

45. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. The Lancet. 2004;328(8520):39-41.

46. Braun V,ova L, Ong BN, et al. Barriers and facilitators to deprescribing in primary care: a systematic review. BJGP Open. 2020. https://doi.org/10.3399/bjgpopen20X101096

47. Swinkels I, Hugens M, Schoenmakers T, et al. Lessons learned from a broad adoption of eHealth in primary health care. J Med Internet Res. 2018;20(3):e83.
48. NHS Health Education England. 2020. The Future Doctor Programme. A co-created vision for the future clinical team. https://www.hee.nhs.uk/our-work/future-doctor (accessed 30 July 2020)

49. Reeve J. GP Scholarship: the WISE GP. 2018. https://sapc.ac.uk/article/gp-scholarship-wise-gp (accessed 30 July 2020)

50. Dohnhammer U, Reeve J, Walley T. Patients’ expectations of medicines – a review and qualitative synthesis. Health Expect. 2016;19(2):179-193.

51. Pound P, Britten N, Morgan M. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med. 2005;61(1):133-155.

52. Reeve J, Cooper L. Rethinking how we understand individual health care needs for people living with long term conditions: a qualitative study. Heal and Soc Care in the Com. 2016;24(1):27-38.

53. Sweller J. Cognitive load during problem solving: effects on learning. Cognit Sci. 1988;12(2):257-285.

54. Guthrie B, Tang J. 2016. What did we learn from 12 years of QOF? http://www.sspc.ac.uk/media/media_486342_en.pdf (accessed 30 July 2020)

How to cite this article: Reeve J. Avoiding harm: Tackling problematic polypharmacy through strengthening expert generalist practice. Br J Clin Pharmacol. 2021;87:76–83. https://doi.org/10.1111/bcp.14531